Hannes Alber
Hannes Alber
Department for Internal Medicine and Cardiology at Klinikum Klagenfurt a. W
Geverifieerd e-mailadres voor kabeg.at
Geciteerd door
Geciteerd door
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial
A Bauer, M Schreinlechner, N Sappler, T Dolejsi, H Tilg, BA Aulinger, ...
The Lancet Respiratory Medicine 9 (8), 863-872, 2021
Neopterin, CD4+ CD28− lymphocytes and the extent and severity of coronary artery disease
HF Alber, C Duftner, M Wanitschek, J Dörler, M Schirmer, ...
International journal of cardiology 135 (1), 27-35, 2009
Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.
HF Alber, M Frick, A Süssenbacher, J Dörler, W Dichtl, EM Stocker, ...
Wiener medizinische Wochenschrift (1946) 157 (3-4), 73-78, 2007
Gender-related outcome following percutaneous coronary intervention for ST-elevation myocardial infarction: data from the Austrian acute PCI registry
A Suessenbacher, J Doerler, H Alber, J Aichinger, J Altenberger, ...
EuroIntervention 4 (2), 271-276, 2008
Chronic heart failure is associated with vascular remodeling of the brachial artery
G Poelzl, M Frick, H Huegel, B Lackner, HF Alber, J Mair, M Herold, ...
European journal of heart failure 7 (1), 43-48, 2005
Vascular endothelial growth factor synthesis in vascular smooth muscle cells is enhanced by 7-ketocholesterol and lysophosphatidylcholine independently of their effect on …
J Dulakk, A Józkowicz, W Dichtl, H Alber, SP Schwarzacher, O Pachinger, ...
Atherosclerosis 159 (2), 325-332, 2001
Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized, placebo …
HF Alber, M Frick, A Suessenbacher, J Doerler, M Schirmer, EM Stocker, ...
American heart journal 151 (1), 139. e1-139. e7, 2006
Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls
B Ezeh, M Haiman, HF Alber, B Kunz, B Paulweber, A Lingenhel, HG Kraft, ...
Journal of lipid research 44 (8), 1523-1529, 2003
High‐density lipoprotein cholesterol, C‐reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography
HF Alber, MM Wanitschek, S De Waha, A Ladurner, A Suessenbacher, ...
European journal of clinical investigation 38 (6), 372-380, 2008
Comparison of peripheral endothelial function in shift versus nonshift workers
A Suessenbacher, M Potocnik, J Dörler, G Fluckinger, M Wanitschek, ...
The American journal of cardiology 107 (6), 945-948, 2011
Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease
HF Alber, M Frick, J Dulak, J Dörler, RH Zwick, W Dichtl, O Pachinger, ...
Heart 91 (3), 365-366, 2005
Short‐and long‐term changes of flow‐mediated vasodilation in patients under statin therapy
M Frick, HF Alber, H Hügel, SP Schwarzacher, O Pachinger, F Weidinger
Clinical Cardiology: An International Indexed and Peer‐Reviewed Journal for …, 2002
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial
NJ Tripolt, E Kolesnik, PN Pferschy, N Verheyen, K Ablasser, S Sailer, ...
American Heart Journal 221, 39-47, 2020
Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic …
A Peer, G Falkensammer, H Alber, A Kroiss, A Griesmacher, H Ulmer, ...
Heart 95 (4), 297-303, 2009
Vascular endothelial growth factor: angiogenesis, atherogenesis or both?
J Dulak, A Jozkowicz, M Frick, HF Alber, W Dichtl, SP Schwarzacher, ...
Journal of the American College of Cardiology 38 (7), 2137-2138, 2001
Empagliflozin in acute myocardial infarction: the EMMY trial
D von Lewinski, E Kolesnik, NJ Tripolt, PN Pferschy, M Benedikt, ...
European Heart Journal 43 (41), 4421-4432, 2022
Is there a relation between non-calcifying coronary plaques and acute coronary syndromes? A retrospective study using multislice computed tomography
G Feuchtner, T Postel, F Weidinger, M Frick, H Alber, W Dichtl, D Jodocy, ...
Cardiology 110 (4), 241-248, 2008
Effect of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the …
G Montalescot, AW van’t Hof, L Bolognese, WJ Cantor, A Cequier, ...
JACC: Cardiovascular Interventions 9 (7), 646-656, 2016
Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes—results from the BASKET PROVE trial
MT Jensen, C Kaiser, KE Sandsten, H Alber, M Wanitschek, A Iversen, ...
International journal of cardiology 168 (4), 3802-3806, 2013
Comparison of brachial artery wall thickness versus endothelial function to predict late cardiovascular events in patients undergoing elective coronary angiography
A Suessenbacher, J Dörler, J Wunder, F Hohenwarter, HF Alber, ...
The American journal of cardiology 111 (5), 671-675, 2013
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20